The U.S. Food and Drug Administration (FDA) has granted Biogen’s investigational drug, litifilimab, Breakthrough Therapy Designation for the treatment of cutaneous lupus erythematosus (CLE).

The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen ...

There are a few to keep in mind.

Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

It's long been known that money woes tend to worsen health outcomes in people with chronic diseases. The demographics of ...

The striking benefits achieved with emerging treatment options for recalcitrant connective tissue diseases offer the ...

This autoimmune disease may impact your skin as well as your nails and hair. Learn what to look for to treat lupus more effectively.

A lupus specialist sheds light on how skin tone can affect diagnosis, revealing why rashes in people of colour are frequently overlooked or misidentified. This explanation explores the medical bias ...

Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the 2025 Global Team ...

The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...